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2Graphical Abstract
3Highlights
1. AgSD nanocrystals improved the dissolution behavior but aggravate the 
cytotoxicty.
2. Encapsulation of AgSD nanocrystals in chitosan hydrogels reduced their 
cytotoxicity.
3. Encapsulation of AgSD nanocrystals in hydrogels facilitated sustained release.
4. Encapsulation of AgSD nanocrystals in hydrogels remained high antibacterial 
activity.
5. Hydrogels containing AgSD nanocrystals showed the best in vivo healing effects.
4Abstract: 
In the present study genipin crosslinked chitosan (CHI) hydrogels, which had been 
constructed and reported in our previous studies (Lei Gao, et al. Colloids Surf. B 
Biointerfaces. 2014, 117: 398), were further evaluated for their advantage as a carrier 
for silver sulfadiazine (AgSD) nanocrystal systems. Firstly, AgSD nanocrystals with a 
mean particle size of 289 nm were prepared by wet milling method and encapsulated 
into genipin crosslinked CHI hydrogels. AgSD nanocrystals displayed a uniform 
distribution and very good physical stability in the hydrogel network. 
Swelling-dependent release pattern was found for AgSD nanocrystals from hydrogels 
and the release profile could be well fitted with Peppas equation. When AgSD 
nanocrystals were encapsulated in hydrogels their fibroblast cytotoxicity decreased 
markedly, and their antibacterial effects against Staphylococcus aureus, Escherichia 
coli and Pseudomonas aeruginosa were still comparable to unencapsulated AgSD 
nanocrystals. In vivo evaluation in excision and burn cutaneous wound models in 
mice showed that AgSD nanocrystal hydrogels markedly decreased the expression of 
inflammatory cytokine IL-6, but increased the levels of growth factors VEGF-A and 
TGF-β1. Histopathologically, the wounds treated by hydrogels containing AgSD 
nanocrystals showed the best healing state compared with commercial AgSD cream, 
hydrogels containing AgSD bulk powders and blank hydrogels. The wounds treated 
by AgSD nanocrystal hydrogels were dominated by marked fibroblast proliferation, 
new blood vessels and thick regenerated epithelial layer. Sirius Red staining assay 
indicated that AgSD nanocrystal hydrogels resulted in more collagen deposition 
characterized by a large proportion of type I fibers. Our study suggested that 
genipin-crosslinked CHI hydrogel was a potential carrier for local antibacterial 
nanomedicines. 
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61. Introduction
It has been proved that skin wounds are susceptible to infections caused by 
gram-positive bacteria like Staphylococcus aureus, and gram-negative bacteria like 
Escherichia coli, Pseudomonas aeruginosa [1]. Infection of wound surfaces often 
causes delayed healing or nonhealing of the wound, which results in mortality [2]. It 
was reported that infection was responsible for 75% of all deaths in patients with 
burns exceeding 40% of the total body surface area [3]. 
Usually skin wounds are rich in exudation and proteins, and consist of avascular 
necrotic tissues, which limit the effective permeation of systemically administered 
antibiotics [4, 5]. Subsequently, topical antibacterial preparations are more suitable in 
these cases. AgSD, a combination of silver and sulfadiazine, is considered as first-line 
drug for topical wound management due to its biocidal activities toward a wide 
spectrum of microorganisms and its wound convergence promoting effects [6]. AgSD 
has dual antibacterial effects. The free silver can react with both sulfhydryl groups of 
bacterial enzymes and DNA, and sulfadiazine can stop the synthesis of DNA by 
interrupting the production of folate [7]. However, the antibacterial effect of AgSD is 
badly limited by its poor aqueous solubility [8]. Moreover, AgSD has been shown to 
be cytotoxic in vitro toward fibroblasts and keratinocytes and consequently to retard 
wound healing in vivo [9]. These two issues limit topical therapeutic effects of AgSD 
to a large extend. 
7Works by us and other groups had proved that nanocrystal technology was an ideal 
approach to handle the poor solubility problem [10-12]. It is anticipated that the poor 
solubility of AgSD could be markedly improved by nanocrystal technology. Then the 
enhanced solubility as well as the increased interaction between drugs and bacteria
caused by the huge surface area can markedly improve their antibacterial effects [13]. 
On the other hand, however, markedly increased surface area after nanosization may 
also aggravate the cytotoxicity of AgSD, which would retard wound healing. In 
addition, physical stability of AgSD nanocrystals would be another problem like other 
antibacterial nanomedicines (such as nano silver, nano ZnO) [14, 15]. Nanocrystals 
will tend to aggregate to reduce the huge surface energy caused by the large interface 
between the solid and the medium [16]. Therefore, a suitable carrier might be 
necessary for the application of AgSD nanosystems on the wound. 
Hydrogels have been considered as excellent wound dressings due to the 
water-saturated networks which mimic the three-dimensional extracellular matrix 
(ECM) and allow for efficient transport of oxygen, nutrients and metabolic products 
[17]. Several reviews had summarized and analyzed the merits of polymer hydrogels 
applied for wound care [18-21]. In our previous work CHI hydrogels were prepared
by using natural genipin as crosslinking agent. Crosslinking with genipin showed no 
influence on the cytocompatibility of CHI and could effectively adjust the stiffness of 
CHI hydrogels which then regulate fibroblast attachment and proliferation [22]. In the 
present research, the genipin crosslinked CHI hydrogels were further studied for the 
advantage as a potential carrier dressing for AgSD nanocrystals.
82. Materials and Methods
2.1. Materials
Silver sulfadiazine was purchased from Dongbei Pharmacy Company; Thiazoyl blue 
tetrazolium bromide (MTT), trypsin and ethylenediamine tetraacetic acid (EDTA) 
were purchased from Sigma Company; CHI (molecular weight: 300–450 kDa; 
viscosity: 500–800 mPa·s; degree of deacetylation: 85–95%), phosphoric acid, 
ammonia solution, formaldehyde, dimethyl sulfoxide (DMSO) and ethanol were 
purchased from Sinopharm Chemical Reagent Co., Ltd. Genipin was purchased from 
Linchuan Zhixin Biotechnology Company (Fuzhou, China); Acetonitrile (Fisher 
Company) was of HPLC grade, other reagents were of analytical grade. Ultrapurified 
water was obtained from a Milli-Q ultrapurification system (Milli-Q® Integral, USA).
2.2. Wet milling
AgSD nanocrystal (AgSD/NCT) suspensions were prepared using a wet-milling 
technique. 0.2g CHI was dissolved in 100 ml water. 10 g of drug powder was 
dispersed in the CHI solution. The obtained suspensions were poured into the holder 
of a nano milling system (Elektromotorenwerk brienz AG) containing 50g of milling 
beads (zirconium oxide, diameter 1 mm). The grinding was performed at 1500 rpm 
9for 20min and 2500 rpm for 20min, and the holder was cooled at 0°C by circulating a 
refrigerant. Particle size reduction was monitored with a Malvern Zetasizer 3000HS 
(Malvern Instrument, Malvern, UK) by taking samples at different time intervals 
during the process. After milling, the nanosuspensions were separated from the 
grinding beads.
2.3. Characterization of nanosuspensions
2.3.1. Particle size and morphology
The particle size and polydispersity indexes (PI) of AgSD/NCT suspensions were 
measured with Malvern Zetasizer (3000SH, Malvern Instruments Ltd., UK). The 
morphology of nanoparticles was observed using transmission electron microscope 
(TEM, JEM-1200EX, Japan). One drop of nanosuspension was placed on a copper 
grid and stained with 2% phosphotungstic acid for 2 min. The grid was allowed to dry 
at room temperature and was examined with the electron microscope. All 
measurements were made in triplicate. 
2.3.2. Dissolution
Dissolution behavior of AgSD/NCT was studied by using a rotary shaker (HZS-HA, 
China). 200mL phosphate buffer solution (PBS, pH = 7.4) at 37? was used as 
dissolution media. Samples containing equivalent of AgSD (10mg) were dispersed 
into dissolution vessel and shaken at 100 rpm. At predetermined intervals, 100μL of 
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medium was withdrawn and centrifuged at 14000 rpm for 15 min at 4? (3K18 
centrifuge, Sigma, Germany). Equal blank medium was compensated immediately 
following each sampling. AgSD content was measured after adequate dilution with 
mobile phase using an Agilent 1290 ultrahigh-pressure liquid chromatograph 
(UHPLC) equipped with a quaternary pump, an auto sampler and DAD UV detector. 
The detection wavelength was set at 260.0 nm. Chromatographic separation was 
carried out with an Agilent Eclipse Plus C18 Column (3.5 μm particle size, 2.1×50mm) 
with mobile phase of 0.1% phosphoric acid/ acetonitrile (94:6, v/v) at 30?. The flow 
rate was 0.30 mL/min. Dissolution profiles of AgSD bulk power (AgSD/Bulk) 
suspensions were also measured under the same conditions. 
2.4. Hydrogel formation
The AgSD/NCT suspension prepared with CHI as stabilizer was diluted using CHI 
solution to obtain a final concentration of 0.1% AgSD and 2% CHI (w/v). To obtain 
hydrogels of different crosslinking levels, different amount of genipin (1.65mM,
2.75mM, 3.30mM and 4.40mM, respectively) were added into the resultant 
suspension followed by vigorous stirring for 2 min at room temperature. Then 1 mL 
of the mixed solutions were poured onto a 10 mm plastic dish and placed in an 
incubator for 24 h at 37?.
2.5. Characterization of hydrogels containing AgSD nanocrystals
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2.5.1. Microstructure of hydrogels
Hydrogels containing AgSD/NCT were firstly frozen at -80? for 24 h and then 
lyophilized. The resulting dried gels were placed on an aluminum mount, coated with 
conductive gold. The morphology of AgSD/NCT immobilized in the gels was 
examined by a JSM-6510 scanning electron microscope (SEM, Japan) at an 
acceleration voltage of 15kV. Hydrogels containing AgSD/Bulk were also observed 
as control.
2.5.2. Drug release from hydrogels
Hydrogels containing 1mg AgSD/NCT or AgSD/Bulk (calculated as pure AgSD) were 
placed in 100 ml of PBS in a flask (For comparison, gels containing AgSD/Bulk were 
prepared at genipin concentration of 1.65mM and 4.40mM). Then the in vitro drug 
releases from hydrogels were evaluated by using a rotary shaker at the same condition 
as shown in section 2.3.2. At predetermined intervals, 50μL of medium was 
withdrawn and centrifuged at 14000 rpm for 10 min at 4? and equal blank medium 
was compensated immediately. Dissolution profiles of a commercial AgSD cream 
were also measured as control. AgSD content was measured by UHPLC method 
described above. Drug release was modelled by Peppas equation Eq. (1) as follow:
nt kt
M
M 
                                             Eq. (1)
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Where Mt/M∞ was the fractional release at time t, k was a rate constant and n was the 
diffusional exponent [23]. 
2.5.3. Stability of nanosuspensions
The physical stability of AgSD/NCT in crosslinked CHI hydrogel was investigated 
after storage for 6 weeks at room temperature. Physical stability of AgSD/NCT 
dispersing in CHI slurry without crosslinking process was also evaluated as control. 
SEM particle morphology and drug release behavior were utilized for evaluation of 
storage stability of AgSD/NCT in hydrogels. Particle size and dissolution velocity 
measurements were used for AgSD/NCT in CHI slurry.
2.6. Biocompatibility studies 
The biocompatibility of AgSD/NCT hydrogel was assessed by MTT assay. L929 
fibroblasts were seeded in 96-well plate at a density of 5×103 cells per well. 
Fibroblasts were cultivated for 24 h to obtain sub-confluence. Then fibroblasts were 
washed with saline solution and 100μL of samples containing 2 μg/ml AgSD (diluted 
with the complete medium) were put in contact with the fibroblasts. The
biocompatibility of blank gel was also evaluated and fresh complete medium was 
used as control. After 48 h incubation, the medium was removed, 20 μL MTT solution 
(5 mg/ml) was added to each well. After 4 h exposure at 37?, the extractants were 
drained off gently and 150 μL of DMSO was added to dissolve the formazan crystals. 
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The dissolved solution was shaken continuously for 10 min by a shaker. The optical 
density of formazan solution was detected by an ELISA reader (Elx800) at 490 nm. 
All assays were done with six parallel samples. The percentage of relative viability%
was calculated by Eq. (2), where ODsamples were absorbance of samples and ODnegative
was of negative control.
%100% 
negative
samples
OD
OD
yValiabilit               Eq. (2)
2.7. In vitro antibacterial activity.
To evaluate the antimicrobial properties of AgSD loaded dressings, the following 
reference bacterial strains were used: Staphylococcus aureus (S. Aureus, ATCC 
25923); Escherichia coli (E. Coli, ATCC 25922); Pseudomonas aeruginosa (P. 
Aeruginosa, ATCC 27853). Before testing, bacteria were grown overnight in standard 
Luria Bertani (LB) medium at 37?. 
AgSD bulk and nanocrystal suspensions and hydrogels containing AgSD nanocrystals 
were evaluated for bactericidal inhibition against S. aureus, E. coli, P. Aeruginosa. LB 
nutrient agar was used as culture media [24]. 100 μL liquid culture medium with 
bacteria was spread on nutrient agar in a Petri dish to create a confluent lawn of 
bacterial growth. Then, 50 μL of different AgSD samples were tailored into small 
pores with diameter of 3 mm. Penicillin & Streptomycin solution and blank hydrogels 
were used as positive and negative control, respectively. Commercial AgSD cream 
was also tested as a reference. The dishes were incubated for 24 h at 37?. The 
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antibacterial activity was determined by measuring the diameter of inhibition zone 
(mm). All experiments were performed in triplicate. 
2.8. Animal experiment
2.8.1. Animals
Kunming male mice weighing between 20~25g were purchased from Experimental 
Animal Center of Academy of Military Medical Science (AMMS, Beijing, China). 
The animal use protocol in this study was reviewed and approved by the Experimental 
Animal center of AMMS. All animal work was conducted according to the national 
and international guidelines. At first, the animals were acclimatized at a temperature 
of 25 ± 2? and a relative humidity of 70 ± 5% under natural light/dark conditions for 
1 week and were fed with food and water ad libitum. Anesthesia was achieved with 
pentobarbital sodium (40 mg/kg, Biomedical, Beijing) prior to skin wounding.
2.8.2. Wound model
The acute burn wound model was performed as described previously, with 
modification [25, 26]. A burn template was made from a 10cm×10cm plastic case 
with a opening window (1cm×1cm) in the middle of the bottom. The dorsum of each 
mouse was carefully shaved and laid on the middle of the burn template after 
anesthesia so that dorsal skin could expose through the opening window. Then the 
exposed dorsal skin of each skin was immersed in 75? for 15 s. This method was 
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used to form a second-degree burn wound [25]. For the excision wound model, the 
dorsal hair of each mouse was shaved, and a piece of full-thickness skin (1cm×1cm) 
was excised with sterilized scissors [26].
In the excision wound and burn models, the mice were divided into 6 groups with 6 
mice for each group: (1) untreated control (Untreated), (2) S. Aureus treatment only 
(Staph), (3) S. Aureus and AgSD cream treatment (Cream), (4) S. Aureus and blank 
gel treatment (Blank Gel), (5) S. Aureus and AgSD/Bulk hydrogel treatment 
(AgSD/Bulk Gel), (6) S. Aureus and AgSD/NCT hydrogel treatment (AgSD/NCT
Gel). AgSD dosage in cream and hydrogels was equivalent to 1mg. For all S. Aureus
treatment groups, we applied 500 μL of S. aureus (1×108 CFU/ml) solution to a piece 
of clean gauze to produce a “bacterial dressing” that was immediately placed on the 
wounds. The wounds were then covered with the “bacterial dressings” and bandaged 
for 24h to let the bacterial solution enter the wound area [27]. One day later, we 
changed the bacterial dressings to therapeutic dressings corresponding to the different 
groups. The wound dressings were changed daily until sacrifice. While changing the 
dressings, a close-up picture of each wound was taken. Wound area closure was 
measured by marking the area on a transparent graph sheet. The exact area of the 
unrecovered wound was remarked and calculated. The results of wound 
measurements on various days were expressed as percentage of wound closure 
calculated by Eq. (3) as follows:
%Wound closure= (Area0 −Areat )/Area0 ×100%  Eq. (3)
  Where the Area0 was the initiative wound area, and the Areat represented the wound 
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area on the measure day.
2.8.3. Collection of tissue
The mice were sacrificed by neck dislocation on the 21st day after cutaneous injury. 
Wound skins were harvested and preserved in 10% neutral buffer formalin for 
histological and collagen deposition examination. Blood samples were also obtained 
and immediately transferred into tubes. After centrifugation at 8000 g for 10 min, the 
serum samples were removed and stored at -80?.
2.9. Measure of cytokine levels
Serum levels of vascular endothelial growth factor (VEGF)-A, interleukin (IL)-6, and 
transforming growth factor (TGF)-β1 were measured with cytokine-specific ELISA 
kits (Dakewei, Shenzhen, China). Each measurement was performed according to the 
manufacturer’s instructions. Cytokine levels in normal mice were used as negative 
control.
2.10. Histopathological analysis
2.10.1  Hematoxylin and eosin (H&E) staining
The gross histopathological changes at the wound site were evaluated by H&E 
staining. The skin tissues fixed in 10% neutral buffer formalin were embedded in 
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paraffin. 5 μm thick tissue sections were obtained and visualized under a light 
microscope after standard H&E staining (E200, Nikon, Japan). Eight random fields 
from different sections in each group were evaluated and scoring was done by the 
method described by Greenhalgh et al. [28]. Briefly, scoring for each field was done 
from 1 to 12 as follows: i) 1 to 3 was given to none to minimal cell accumulation and 
granulation tissue; ii) 4 to 6 to thin immature granulation tissue that was dominated by 
inflammatory cells but has few fibroblasts, capillaries, or collagen deposition and 
minimal epithelial migration; iii) 7 to 9 to moderately thick granulation tissue which 
could range from being dominated by inflammatory cells to more fibroblasts and 
collagen deposition, extensive neovascularization, with epithelium ranging from 
minimal to moderate migration; and iv) 10 to 12 to thick, vascular granulation tissue 
dominated by fibroblasts and extensive collagen deposition, with epithelium partially 
to completely covering the wound.
2.10.2. Picrosirius red staining for collagen
Assessment of collagen in wound sections was done by staining with picrosirius red 
(Direct Red 80, Sigma Aldrich, USA) through a modified picrosirius procedure [29]. 
According to the birefringence pattern, collagen types were differentiated as (i) thick 
and denser collagen showing orange to red color and (ii) thinner collagen fibers 
showing green [30]. Stained sections were viewed under polarized light (DMI6000I, 
Leica, Germany) and quantification of collagen amounts was done in six random 
images from each group by using ImageJ software (Version 1.44).
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2.11. Statistical analysis
All data were expressed as means ± standard deviation (SD). A one-way analysis of 
variance (ANOVA) was performed with SPSS software (Version 19.0). Significance 
was determined at P<0.05.
3. Results
3.1. Particle size and morphology
Particle sizes and PIs of AgSD nanocrystals during milling progress were shown in 
Supplementary Fig. 1. Routinely, the mean diameters of bulk AgSD crystalline drug 
materials were tens of micrometers and the size distributions were broad. With 
increasing milling velocity and times, the sizes gradually decreased to 0.290 μm and 
the PIs settled around 0.240~0.250. 
The morphology of AgSD nanocrystals was observed using TEM (Supplementary Fig. 
1B). After milling, AgSD bulk powders were transformed into flaky shape 
nanocrystals in the presence of the stabilizers. The particle size ranged from 200~400
nm, which was consistent with the data from Zetasizer. 
3.2. Dissolution of AgSD nanocrystals
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As shown in Supplementary Fig. 2, AgSD nanosuspensions exhibited a dramatic 
increase in drug dissolution rate compared with un-milled AgSD suspensions with the 
same stabilizer composition. The dissolution rate of nanoparticles was so fast that 
60.9% had dissolved immediately after 1 min and almost all drugs had dissolved 
within 15 min. In contrast, less than 20% of AgSD was dissolved after 6h from the 
bulk suspensions.
3.3. Microstructure of hydrogels containing AgSD nanocrystals
Figure 1. 
As shown in Fig. 1, macroporous sponge-like scaffolds with pore size ranging from 
100μm to 200μm could be obtained upon a lyophilization process. After further 
magnification well-dispersed AgSD nanocrystals could be found within the network, 
without obvious aggregations. AgSD nanocrystals maintained their initial particle size 
ranging from 200nm to 400nm inside the network. In hydrogels containing bulk 
AgSD powders, particle size of drugs was in range of tens of micrometers. 
3.4. Drug release 
After 48h, cumulative AgSD release was 92.49%, 73.70%, 66.84% and 55.23% for 
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gels containing AgSD nanocrystals (Fig. 2A). It could be seen that the AgSD release 
rate from hydrogels decreased with increase of crosslinking density. On the other 
hand hydrogels containing AgSD nanocrystals released much faster than those 
containing AgSD bulk powders at a given crosslinking level (92.49% vs 52.78% for 
hydrogel with 1.65mM genipin; 55.23% vs 32.37% for hydrogel with 4.40mM 
genipin). It only reached 27.09% for commercial AgSD cream. The kinetic constant k 
and diffusion constant n of different gels were shown in Table 1. It could be seen that 
all release curves of different gels could be well fitted with the equation with 
coefficient R ranging from 0.958 to 0.978. 
Figure 2?
Table 1?
3.5. Stability 
After 6-week storage, AgSD/NCT in CHI slurry showed visible caking and 
sedimentation on the bottom of the vial, but could be redispersed after moderate hand 
shaking. The mean particle size had increased to about 3.5μm and PI to 0.57 
(Supplementary Fig. 3). When dissolution test as described in section 2.3.2 was 
carried out on AgSD/NCT suspensions after 6-week storage, dissolution velocity
markedly decreased (only about 60% had dissolved within 6h) compared to the 
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freshly prepared AgSD/NCT suspensions. For the AgSD nanoparticles incorporated in 
hydrogels, however, SEM images indicated the original particle size of nanocrystals 
encapsulated in hydrogels could be maintained after 6-week storage (Fig. 1B). 
Besides, no obvious changes could be seen in the drug release behavior compared to 
the freshly prepared hydrogels (Fig. 2B).
3.6. Biocompatibility study 
The relative viability (%) of L929 fibroblasts after 48h incubation was shown in 
Supplementary Fig. 4. At the same drug concentration, AgSD nanocrystals showed 
much lower viability (48.56%) than bulk powder (68.28%). However, when the AgSD 
nanocrystals were incorporated in hydrogels, their inhibition effects on cellular 
growth were significantly reduced. Correlation between cell viability and crosslinking 
level could be seen. AgSD nanocrystal hydrogels crosslinked with 1.65mM genipin
showed the lowest viability of 70.14%, when the genipin amount increased to 4.4mM 
cell viability could increase to almost 100%. Blank gels (4.4mM genipin) showed 
higher cell viability compared with negative control but with no statistical 
significance (P<0.05). Cell viability of AgSD cream was only 48.86%, significantly 
lower than hydrogels containing the same drug concentration. 
3.7. In vitro antibacterial activity.
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Table 2?
The inhibitory activity was determined against S. aureus, E. Coli and P. Aeruginosa 
respectively. Except for blank hydrogels, distinct inhibition zones were distinctly 
obtained for positive control and all AgSD formulations (Table 2). AgSD/NCT 
suspensions showed larger zone diameter on three bacteria than AgSD/Bulk 
suspensions, although significant difference only could be seen in S. aureus and P. 
Aeruginosa groups. After incorporated in hydrogels, AgSD/NCT showed slightly 
decreased zone diameter (P>0.05), but still had significantly larger zone diameter than 
positive control (P<0.05). AgSD/NCT hydrogels were also significantly more 
effective than AgSD cream against S. aureus (P<0.05). 
3.8. Wound contraction rate
Figure 3.
During the healing process, wound contraction of the open wound area was observed, 
and results were shown in Fig. 3. In the acute burn model, the AgSD/NCT hydrogel
had significantly smaller wound areas on day 14 and day 21 compared with other 
therapeutic groups (P<0.05). AgSD/Bulk hydrogel resulted in significantly smaller 
wound areas compared with AgSD cream on day 21 (P<0.05). Blank gel group also 
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showed larger closure than AgSD cream but with no statistical significance (P>0.05). 
The excision wound model showed similar results. The wound area in the AgSD/NCT 
hydrogel group was significantly smaller than the other 5 groups on day 7, day 14 and 
day 21 (P<0.05). AgSD/Bulk hydrogel also led to significantly smaller wound areas 
compared with AgSD cream on day 21 (P<0.05). However, blank gel group remained 
lager wound areas than cream group on day 21 in excision model, but having no 
significance (P>0.05). 
3.9. Measure of cytokine levels
Table 3. 
The effects of different treatment on the cytokine levels were shown in Table 3. In the 
burn model, the serum VEGF-A level in three AgSD containing dressings were 
significantly higher than that in Staph group (P<0.05). VEGF-A level in AgSD/NCT 
hydrogel group was higher than that in commercial cream group, but without any 
significance. TGF-β1 level in AgSD/NCT hydrogel, AgSD/Bulk hydrogel, AgSD
cream and blank gel groups was all significantly higher than that in Staph group 
(P<0.05). Conversely, AgSD/NCT hydrogel, AgSD/Bulk hydrogel and AgSD cream 
significantly reduced IL-6 levels compared to Staph group. The down regulation of 
blank hydrogel on IL-6 level had no significance compared to that of Staph group. In 
the excision model, only AgSD/NCT hydrogel group had VEGF-A level significantly 
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higher than Staph group, which was also markedly higher than Cream group. Only 
AgSD/NCT hydrogel had TGF-β1 level markedly higher than Staph group. IL-6 level 
in AgSD/NCT hydrogel, AgSD/Bulk hydrogel and Cream groups was all significantly 
lower than that in Staph group (P<0.05). And the reduction effect of both AgSD/NCT 
hydrogel and AgSD/Bulk hydrogel on IL-6 level was markedly stronger than that of 
AgSD cream.
3.10 Histological analysis
The H&E stained sections of healing burn wounds of different groups on the 21st day 
were presented in Fig. 4A. Scabs could still be observed in Untreated, Staph, Cream 
and blank gel groups. The wound sections of Untreated and Staph groups still showed 
presence of infiltration of inflammation cells with few capillaries and epithelial cells. 
In wound sections of Cream and blank gel groups, slight inflammatory reaction still 
existed along with thin epithelial layer and obvious proliferation of fibroblast. In 
wound sections of AgSD/Bulk hydrogel and AgSD/NCT hydrogel groups, fibroblasts 
had been predominant with almost no inflammatory reaction observed. Moreover, the 
AgSD/NCT hydrogel group was characterized by thick epithelial layer and many 
newborn blood vessels. Fig. 4B also showed the sections of excision wounds of 
different groups on the 21st day. Scabs were seen in Untreated and Staph groups, 
where inflammatory cell infiltration and gathering of macrophages were present. As 
was the case in burn model, the wound sections of Cream and blank gel groups 
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showed thin epithelial layer and mild fibroblast proliferation with slight inflammatory 
reaction, and wound sections of AgSD/Bulk hydrogel and AgSD/NCT hydrogel
groups presented thick epithelial layer and newborn blood vessels with flourishing 
fibroblasts. Histological scoring of blank gel group was significantly higher than that 
of Staph group in both wound models (P<0.05). Histological scoring of Cream group 
was markedly higher than that of Untreated and Staph groups in both models (P<0.05), 
but significantly lower than AgSD/NCT hydrogel group (P<0.05).
3.11 Collagen deposition analysis
Table 4?
The representative picrosirius red stained sections of burn and excision wounds in 
mice from different groups on the 21st days were presented in Fig. 4A. In both wound 
models, the collagen fibers in the sections of Untreated and Staph groups mainly 
exhibited irregular greenish birefringence under polarized microscope. The proportion 
of green fibers in Cream and blank gel groups was lower than that of Untreated and 
Staph groups, but the orange fiber proportion was more. The orange fibers were 
predominant in AgSD/Bulk hydrogel and AgSD/NCT hydrogel groups. Quantitative 
analysis of collagen fibers (Table 4) showed that on the 21st day AgSD/NCT hydrogel
group showed significantly higher total collagen fiber amount than AgSD cream 
group in both wound models (P<0.05). In addition, the ratio of type I collagen
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concentration to type III collagen concentration in AgSD/NCT hydrogel group was 
the highest among all the treated groups. While the Untreated and Staph groups had 
very low ratio of type I collagen amount to type III. 
4. Discussion
In our present study, AgSD was comminuted to nanosized crystals by wet milling 
method. According to Ostwald–Freundlich equation and Noyes–Whitney equation [31, 
32], it was generally thought that the huge surface area and saturation solubility 
resulting from particle radius in nanometer range leaded to the increased and 
accelerated dissolution velocity. This would be conductive to formation of high 
concentration gradient and then enhanced antibacterial activity on the wound surface.
However, one issue should be paid more attentions despite the benefits generally 
brought by the increased dissolution rate. Extremely high dissolution rate of AgSD 
nanocrystals might result in too high local peak concentration, which might result in a 
short therapeutic action and also aggravate its cytotoxicity. When sustained drug 
release and reduction of cytotoxicity were expected, incorporation of drug 
nanocrystals in biodegradable hydrogels might be a promising approach.
The SEM images displayed that the crosslinking process had no effects on particle 
size and dispersion of nanocrystals inside the gels (Fig 1). Although the size 
dimension was kept in nanometer range, nanoparticles incorporated inside the gels no 
longer showed a burst dissolution behavior in PBS like the unencapsulated 
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nanocrystals. Hydrogels of different crosslinking level exhibited a sustained and 
stable release within 48h (Fig 2A). All the release curves of hydrogels fitted well with 
Peppas equation, which was generally considered to be applicable for drug release 
from swellable matrix. In Peppas equation, rate constant k is a kinetic constant, a 
higher value of k suggests a burst release of drug from matrix. Diffusional exponent n, 
calculated from the slope of the natural logarithmic values of fractional release as a 
function of time, provides an indication of the release mechanism and generally 
ranges from 0.5 to 1. An n value of 0.45 indicates Fickian diffusion whereas a value 
of 0.45–0.89 indicates anomalous transport, as there exists an influence of swelling 
and/or erosion [23]. The kinetic constant k generally became lower with the increase 
of crosslinking extent of hydrogels (Table 1). The diffusional exponent n values 
ranged from 0.549 to 0.626, indicating that drug released from hydrogels through a 
swelling dependent mechanism, i.e drug release was limited by the hydration and 
swelling of the hydrogels in medium. To further verify the existence of correlation 
between crosslinking level and drug releasing behavior, we made a correlation study 
by using amount of crosslinking agent as x axis and the product of k and n as y axis 
(Fig. 2A). As a result a correlation coefficient R2 of 0.965 could be obtained, which 
also supported the swelling-dependent release pattern for hydrogels.
Our studies demonstrated that after 6-week storage particle growth and aggregation 
could be observed for nanocrystals dispersed in CHI slurry. Aggregation of 
nanocrystals mainly arises from the natural tendency of the nanoparticles to reduce 
the huge surface energy caused by the large interface between the solid and the 
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medium [33]. Only coverage of stabilizers on the surface by non-covalent anchoring 
may not be enough to electrostatically or sterically stabilize the nanoparticles in 
suspension [34]. Moreover, nanoparticles highly dispersed in liquid tend to grow, 
which is called the Ostwald ripening phenomenon [35]. For the two reasons, particle 
size of nanocrystals tends to grow in liquid which finally leads to aggregation and 
caking. If the viscous CHI solution was further crosslinked, then nanocrystals were 
homogeneously and individually immobilized in situ and aggregation among 
nanoparticles could not occur any more. Meanwhile the Ostwald ripening 
phenomenon was also prevented due to the lack of free water for molecule solvation 
and migration inside the network [36]. Because hydrogels could not be tested with 
laser particle size analyzer, so distribution and agglomeration degree of AgSD 
nanocrystals were assessed by SEM images. Individual nanocrystals were still visible 
and well-distributed throughout the network after 6-week storage. The maintenance of 
uniform dispersion of AgSD nanocrystals in hydrogels was crucial to keep a stable 
and controlled drug release behavior.
Biocompatibility studies showed that AgSD was cytotoxic toward fibroblasts, which 
was in agreement with findings by other authors [9]. At the same drug concentration, 
AgSD nanocrystals showed less cell viability compared to AgSD bulk powders. It 
could be explained by the increased interaction between fibroblasts and particles
caused by the high surface-to-volume ratio of nanocrystals and also the higher 
dissolved drug concentration resulted from the significant improved solubility. The 
encapsulation of AgSD nanocrystals in hydrogels significantly decreased the 
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cytotoxic effect against fibroblasts. Generally, cytotoxic effect was associated with 
crosslinking level, hydrogel of higher crosslinking level showed lower cytotoxic 
effect. It might be because AgSD released from hydrogels of higher crosslinking level 
at a slower rate. Similar result had been reported by Lee et al, who found that cellular 
damage could be minimized by the sustained release of AgSD from collagen 
membrane [37]. The blank hydrogels displayed higher cell viability than negative 
control even at the highest crosslinking agent concentration, which was consistent 
with our previous report [22]. Interestingly, commercial AgSD cream at the same 
AgSD concentration showed higher cytotoxicity than AgSD bulk powders. Maybe the 
solubilization effect and cytomembrane permeability prompting effect of surfactants 
existing in the cream aggravated the cytotoxicity of AgSD [38].
Taking into consideration of low cytotoxicity effect and sustained release, we chose 
hydrogel with 4.40mM genipin for the antibacterial studies and wound healing 
experiments. AgSD/NCT suspensions showed larger inhibition zone size against three 
bacteria than AgSD/Bulk suspensions, which could also be explained by the enhanced 
interaction with bacteria and increased solubility of AgSD/NCT. When incorporated 
in hydrogel AgSD/NCT displayed nearly the same zone size as unencapsulated 
nanocrystals. It indicated that extended release of AgSD from hydrogel contributed to 
lower cytotoxicity against fibroblast, but meanwhile it could ensure a sufficient in 
vitro antibacterial effect. This was probably because that the porous structure of the 
hydrogel contributed to penetration of bacterial liquid and a sufficient contact between 
bacteria and drugs release from the network.
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Acute cutaneous wound often inspires the regulation of various cytokines which play 
very important role in various physiological activities of wound healing, including 
inflammation reaction, reestablishment of blood vessels, fibroblast proliferation or 
collagen synthesis [39]. In the present study, VEGF-A, TGF-β1, and IL-6 were chosen 
to represent three different aspects of the wound healing process after different 
treatments, i.e., angiogenesis, fibrogenesis, and inflammation [40-42]. VEGF-A is an 
important growth factor involved in vasculogenesis and angiogenesis, which 
subsequently support the high metabolic activity for cell proliferation and collagen 
synthesis [40]. Results in Table 3 showed that VEGF-A serum levels in AgSD/Bulk
hydrogel and AgSD/NCT hydrogel groups were sharply up-regulated in both 
cutaneous wound models. Accordingly, new blood vessels could be clearly seen in 
H&E stained images of the two groups (Fig. 4A). TGF-β1 is a key cytokine that 
induces differentiation of fibroblasts into myofibroblasts which are in charge of
collagen synthesis [42]. In the early phase of healing wounds, fibroblasts are recruited 
and induced in granulation tissue to synthesize collagen fibers rich in thin and loose 
type III collagen (green fibers after stained by picrosirius red) [43]. As the tissue 
recovery process advances, the granulation tissue is replaced by a more resistant 
tissue rich in type I collagen which is the main component of a mature scar (orange 
fibers after stained by picrosirius red) [43]. The high expression of TGF-β1 in 
AgSD/Bulk hydrogel and AgSD/NCT hydrogel groups stimulated the fibroblasts to 
produce a dense collagen network. The great majority of collagen in wound sections 
of the two groups was type I fibers, indicating an almost complete wound healing. On 
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the contrary, type III fibers accounted for a large proportion in Staph groups and 
Untreated groups of the two models, indicating that the wound healing was still in the 
initial phase. At 21 days post cutaneous injury the Staph groups (especially in burn 
model) still had high serum levels of IL-6, a kind of cytokine released by 
inflammatory cells in excessive inflammation. Accordingly, H&E stained images of 
Staph groups presented severe inflammation reaction. However, almost no 
inflammation could be seen in AgSD/Bulk hydrogel and AgSD/NCT hydrogel groups, 
which showed significantly lower IL-6 level. 
The best healing effects of AgSD/NCT gels could be attributed to several reasons. 
Firstly, the moist local environment provided by hydrogels was conducive to wound 
healing [44]. Kant et al reported the similar results, they found that blank Pluronic 
F-127 gel gave rise to faster wound healing rate than normal saline due to its ability to 
provide a moisture environment to the wound surface [45]. Besides, CHI itself had 
been proved to have the ability to improve the ECM remodeling phase of wound 
healing [46]. Therefore, in our present study, blank gels leaded to faster wound 
closure, more collagen deposition but less inflammation reaction compared to 
Untreated and Staph groups. Secondly, antibacterial ability of AgSD could eliminate 
the destruction effects of bacteria on wound healing. Apart from this, AgSD also 
possesses ability to facilitate wound convergence, formation of granulation tissue and 
finally scar maturation [47]. After nanosization the antibacterial and wound 
convergence promoting abilities of AgSD were further enhanced compared to those of 
bulk powders due to the significant increase of interaction surface area. Thirdly, 
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encapsulation of AgSD in hydrogels significantly reduced its cytotoxic effect against 
fibroblasts. All of these contributed to the best wound healing effects of AgSD/NCT 
hydrogels.
5. Conclusion
The present work mainly studied the advantage of genipin crosslinked CHI hydrogels 
as potential carriers for AgSD nanosystems. AgSD nanocrystals with a mean particle 
size of 289nm were successfully prepared using wet milling technology. Although 
AgSD nanocrystals significantly enhanced the dissolution rate and in vitro
antibacterial activity compared to bulk powders, the poor physical stability and severe 
cytotoxicity to fibroblasts were intractable disadvantages for clinical usage. To solve 
these issues AgSD nanocrystals were further encapsulated into CHI hydrogels. After 
immobilized in the hydrogels, AgSD nanocrystals displayed a very good physical 
stability and a swelling-dependent drug release pattern fitting well with Peppas 
equation. AgSD nanocrystals, immobilized in hydrogels, could significantly enhance 
the in vitro antibacterial effects due to the increased interaction area whilst their 
cytotoxicity had been significantly reduced. In vivo evaluation in excision and burn 
wound mice models showed that wounds treated with the AgSD/NCT containing 
hydrogels had the fastest healing rate, most collagen deposition and almost complete 
re-epithelialization compared to other dressings including AgSD cream, blank 
hydrogels and hydrogels containing AgSD/Bulk. Our findings proved that genipin 
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crosslinked CHI hydrogel was a promising carrier for nanomedicines for local wound 
treatment.  
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Figure captions
Fig. 1. (A) Comparison of genipin crosslinked CHI hydrogels containing AgSD 
nanocrystals and AgSD bulk powders. (B) SEM image of AgSD/NCT after 6-week 
storage.
Fig. 2. (A) AgSD release profiles from CHI hydrogels of different crosslinking level 
and commercial cream. Values are expressed as means ± SD (n = 4). The insert graph 
showed the correlation between genipin level in hydrogels and product of k and n. (B) 
Drug release profile of freshly prepared AgSD/NCT hydrogels and AgSD/NCT 
hydrogels after 6-week storage.
Fig. 3. Photographs and wound closure% of wounds at 7, 14 and 21 days. (A) 
Photographs of wounds treated by different dressings at 0, 7, 14 and 21 days post burn 
or excision injury; (B) Wound closure% of wounds at 7, 14 and 21 days post burn 
injury and excision injury (n=6, * P< 0.05, vs Staph group; ?P< 0.05, vs AgSD cream 
group; # P< 0.05, vs AgSD/Bulk hydrogel group).
Fig. 4. (A): H&E and Sirius red stained images of burn or excision mice (a: Untreated 
group; b: Staph group; c: Cream group; d: Blank gel group; e: AgSD/Bulk hydrogel 
group; f: AgSD/NCT hydrogel group; BV: blood vessels; E: epithelial layer; F: 
fibroblasts; I: inflammation cells; M: macrophages). In the H&E images, the scab still 
could be seen in Untreated and Staph groups, as well as inflammatory cell infiltration 
and macrophage gathering. Fibroblasts, collagen deposition and epithelial layer were 
hardly observed in the two groups. Slight inflammatory cell infiltration still could be 
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seen in granulation tissues of Cream and blank gel groups, but also the moderate 
collagen deposition, fibroblast proliferation and thin epithelial layer; Fibroblasts were 
dominant in AgSD/Bulk and AgSD/NCT hydrogel groups with dense collagen fibers, 
thick epithelial layer and almost no inflammatory cell. (B) The average H&E scoring 
of different wound sections (n=6, *P<0.05, vs Staph group; ?P<0.05, vs AgSD cream 
group; #P<0.05, vs AgSD/Bulk hydrogel group).
41
A
B
Fig. 1.
42
A
B
Fig. 2.
43
A
B  
Fig.  3.
44
A
B
Fig.  4.
45
Table 1. Parameters of drug release profiles of different hydrogels
Sample k n R
AgSD/NCT Gel-1.65mM 0.15 0.549 0.969
AgSD/NCT Gel-2.75mM 0.10 0.626 0.958
AgSD/NCT Gel-3.30mM 0.11 0.552 0.978
AgSD/NCT Gel-4.40mM 0.08 0.587 0.972
AgSD/Bulk gel-1.65mM 0.084 0.538 0.975
AgSD/Bulk gel-4.40mM 0.055 0.536 0.970
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Table 2. Zone diameter of inhibition values (mm) of different AgSD formulations 
against S. aureus, E. coli and P. aeruginosa (means±SD, n=3)
S. aureus E. coli P. aeruginosa
Positive 14 ± 0.9 13 ± 1.9 10 ± 0.6
AgSD cream 15 ±1.5 12 ± 0.6 13 ± 0.9 a,b
Blank gels 5 ± 0.5 a,b,c 5 ± 0.5 a,b,c 4 ± 0.2 a,b,c
AgSD/NCT gels 17 ± 0.8 b 13 ± 1.1 15 ± 0.3 a,b
AgSD/Bulk 14 ± 1.5 11 ± 1.4 12 ± 0.9 c
AgSD/NCT 18 ± 0.8 a,b,c 14 ± 2.0 15 ± 0.4 a,b
a, P<0.05,vs AgSD/Bulk; b, P<0.05,vs Positive; c, P<0.05,vs AgSD cream
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Table 3. Average serum concentration of VEGF-A, TGF-β1 and IL-6 in burn and 
excision mice (means±SD, n=6)
Cytokines Untreated Staph Cream Gel AgSD/Bulk AgSD/NCT
Burn model
VEGF-A 
(pg/ml)
113.8 ±
7.8
128.5 ±
26.8
247.0 ±
83.1a
133.7 ±
27.3c
199.5 ±
20.4a
303.7 ±
34.3a,c  
TGF-β1 
(ng/ml)
9.9 ± 2.1a 5.6 ± 3.9 10.7 ±2.2a
10.5 ±
1.9a
11.4 ±
1.3a
12.3 ± 5.2a  
IL-6 
(pg/ml)
400.4 ± 175.7 522.3 ± 47.0 197.0 ± 56.6a
394.7 ± 
111.0
274.9 ± 35.5a 217.3 ± 38.9a
Excision 
model
VEGF-A 
(pg/ml)
188.3 ± 42.7 187.5 ± 57.0 231.9 ± 52.6 190.6 ± 93.0 231.0 ± 76.1
435.1 ± 
99.0a,b,c
TGF-β1 
(ng/ml)
11.3 ± 2.0a 7.7 ± 3.1 10.9 ± 0.5 10.7 ± 2.1 10.4 ± 4.0 13.8 ± 3.8a
IL-6 
(pg/ml)
307.5 ± 80.6 394.2 ± 28.4
271.7 ± 
12.2a,c
292.3 ± 72.1
237.6 ± 
22.6a,b
87.8 ± 35.6a,b,c
a P< 0.05, vs Staph group; b P< 0.05, vs AgSD cream group; c P< 0.05, vs AgSD/Bulk
hydrogel group.
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Table 4. Average values of type I and type III collagen fiber concentration (%) and the 
ratio of type I to type III (means±SD, n=6)
Untreated Staph Cream Gel AgSD/Bulk AgSD/NCT
Burn model
Collagen type I 1.25 ± 0.86 0.58 ± 0.28 4.51 ± 1.48a,b,c 3.91 ± 1.20a,c 7.31 ± 2.05a,b 10.86 ± 1.41a,b,c
Collagen type III 10.33 ±3.29 9.35 ± 2.06 8.85 ± 1.75 9.44 ± 2.44 7.43 ± 0.98 4.98 ±1.65a,b
Collagen I+III 11.58 ±3.46 9.93 ± 1.87 13.36 ± 2.24a 13.34 ± 1.74a 14.74 ±2.11a 15.84 ± 1.45a,b 
Ratio of I to III 0.13 ± 0.11 0.07 ± 0.04 0.53 ± 0.19a 0.47 ± 0.27 1.00 ± 0.36a 2.53 ± 1.41a
Excision model
Collagen type I 2.54 ± 2.12 1.38 ± 0.33 9.45 ± 3.13a 7.02 ± 1.60a 12.44 ±3.89a 17.88 ± 5.20a,b
Collagen type III 9.78 ± 2.83 9.00 ± 1.94 5.92 ± 2.92a 7.28 ± 2.00 4.82 ± 2.03a 2.95 ± 2.31a,b
Collagen I+III 12.29 ±1.97 10.37 ±1.74 15.37 ± 3.08a 14.30 ± 2.44a 17.26 ±3.40a 20.82 ± 3.38a,b,c
Ratio of I to III 0.34 ± 0.38 0.16 ± 0.05 2.18 ±1.51 1.02 ± 0.32 4.51 ± 6.12 9.49 ±7.04a,b
a P< 0.05, vs Staph group; b P< 0.05, vs AgSD cream group; c P< 0.05, vs AgSD/Bulk hydrogel 
group.
